Year: 2017
Type: article
Study design: Observational Study
Abstract: Prevention of age-related cognitive decline is an increasingly important topic. Recently, increased attention is being directed at understanding biological models of successful cognitive aging. Here, we examined resting-state brain regional low-frequency oscillations using functional magnetic resonance imaging in 19 older adults with excellent cognitive abilities (Supernormals), 28 older adults with normative cognition, 57 older adults with amnestic mild cognitive impairment, and 26 with Alzheimer's disease. We identified a "Supernormal map", a set of regions whose oscillations were resistant to the aging-associated neurodegenerative process, including the right fusiform gyrus, right middle frontal gyrus, right anterior cingulate cortex, left middle temporal gyrus, left precentral gyrus, and left orbitofrontal cortex. The map was unique to the Supernormals, differentiated this group from cognitive average-ager comparisons, and predicted a 1-year change in global cognition (indexed by the Montreal Cognitive Assessment scores, adjusted R2 = 0.68). The map was also correlated to Alzheimer's pathophysiological features (beta-amyloid/pTau ratio, adjusted R2 = 0.66) in participants with and without cognitive impairment. These findings in phenotypically successful cognitive agers suggest a divergent pattern of brain regions that may either reflect inherent neural integrity that contributes to Supernormals' cognitive success, or alternatively indicate adaptive reorganization to the demands of aging.
Source: Cerebral Cortex
Authors: Xixi Wang, Ping Ren, Timothy M Baran, Rajeev D S Raizada, Mark Mapstone, Feng Lin, the Alzheimer’s Disease Neuroimaging Initiative
Language: English
Subfield: Cognitive Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: bronze
Funders: U.S. Department of Defense, Foundation for the National Institutes of Health, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Biogen, F. Hoffmann-La Roche, Medpace, Meso Scale Diagnostics, Synarc, Alzheimer's Disease Neuroimaging Initiative, BioClinica, University of Rochester, Novartis Pharmaceuticals Corporation, Northern California Institute for Research and Education, National Natural Science Foundation of China, Eisai, Servier, IXICO, National Institutes of Health, Genentech, University of California, Los Angeles, University of California, San Diego, Canadian Institutes of Health Research, National Institute on Aging, National Institute of Nursing Research, National Institute of Biomedical Imaging and Bioengineering, DoD Alzheimer's Disease Neuroimaging Initiative
Awards: G1012222616, G104586243, G139833336, G1554142629, G1593117279, G1650819308, G1823308732, Alzheimer's Disease Neuroimaging Initiative, G205795368, G2100670906, G2105457377, G2152643862, G2189010064, G2340207221, G2409989180, G2423387114, G2522063444, G2835601961, G29951154, G3130427885, G3131374986, G3146424788, G3216574877, G3553156159, G3705772492, G3710456697, G3752451908, G3870774570, G3908963977, G3966393351, G4119534169, G43180419, G4337740488, G4401988282, G4475667458, G4501223628, G4800177743, G4860885537, G5207404921, G5209990037, G528601746, EFFECTS OF TRAUMATIC BRAIN INJURY (TBI) AND POST TRAUMATIC STRESS DISORDER (PTSD) ON ALZHEIMER'S DISEASE (AD) IN VETERANS USING IMAGING AND BIOMARKERS IN THE AD NEUROIMAGING INITIATIVE (ADNI)", G5389965057, G5654639750, G5740349702, G5850682332, G613619302, G6173816828, G6210868510, G6371410416, G6412110892, G6447063303, G6719828067, G6792506723, G6899163935, G6948409098, G72415811, G7298697282, G7414321945, G764699806, G7799614282, G781725486, G8228018387, G8281378126, G839208290, G8433417770, G8636843673, G8852128998, G8895907669, G8957659042, G9000039018, G9000074849, G9000103474, G9000122335, G9000181810, G9000345485, G920654007
OpenAlex ID: W2803047665